GIST
Novartis cancer drug beating path to NHS
October 17, 2014Sales and Marketing GIST, Glivec, NHS, NICE, imatinib, uturn
NICE has issued final draft guidance recommending Novartis’s Glivec for up to three years in people who have had a …
Glivec cleared for longer use in GIST patients
February 28, 2012Sales and Marketing Europe, GIST, Gleevec, Glivec, Novartis
Glivec has gained EU approval for extended use after surgery for adults with KIT (CD117)-positive gastrointestinal stromal tumours (GIST).The drug …
FDA fast-tracks Bayer’s GIST drug regorafenib
May 10, 2011Sales and Marketing Bayer, GIST, regorafenib
The assessment of Bayer HealthCare’s investigational drug regorafenib is to be fast-tracked by US authorities for the treatment of stomach …
Novartis ends phase III trial of Tasigna
April 12, 2011GIST, Glivec, Novartis, Tasigna
Novartis has stopped a late stage study of Tasigna for certain types of stomach cancers after it failed to show …
Bayer’s regorafenib gains orphan status for GIST
February 4, 2011Research and Development, Sales and Marketing Bayer, FDA, GIST, gastrointestinal stromal tumours, orphan drug, regorafenib
Bayer’s investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumours (GIST) …
NICE recommends Herceptin for gastric cancer, blocks high dose Glivec
November 24, 2010Sales and Marketing Cancer, GIST, Glivec, HER2, Herceptin, NICE, gastric cancer
NICE has recommended Roche’s cancer drug Herceptin for patients with HER2 metastatic gastric cancer. NICE was initially minded not to …
